Diclofenac Epolamine
Who holds supplier records for Diclofenac Epolamine? 5 organisations hold a current record for Diclofenac Epolamine: an active US FDA Type II Drug Master File. A further 3 organisations have only historical (inactive) DMF filings. Recorded organisation countries for current records: India (1), United States (1), China (1) and Taiwan (1); not recorded for 1.
Most records are filed under another form of this substance: Diclofenac Sodium (16 current sources), Diclofenac Potassium (8 current sources). A DMF or CEP is listed under the form it names.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Diclofenac Epolamine: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/diclofenac-epolamine
Reading the evidence
- 5 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- No company-level GMP certificate matched
No current EU or UK GMP certificate was matched to these organisations. That is not a negative finding; ask each candidate for its certificate and latest inspection outcome.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Diclofenac Epolamine expires 20 Feb 2035. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (5)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Diclofenac Epolamine. Country is the organisation's recorded country, not necessarily the manufacturing site.
- AMOLI ORGANICS PRIVATE LTDIndiaActive DMF 25224 · latest filing Sept 2011
- CAMBREX CHARLES CITY INCUnited StatesActive DMF 26112 · latest filing May 2012
- HENAN DONGTAI PHARM CO LTDChinaActive DMF 44824 · latest filing Sept 2026
- SYN-TECH CHEM AND PHARM CO LTDTaiwanActive DMF 24962 · latest filing May 2011
- YUNG ZIP CHEMICAL IND CO LTDActive DMF 23909 · latest filing Jun 2010
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Historical records (3)
Organisations whose Type II DMFs for Diclofenac Epolamine are no longer active. These show a past filing, not current supply.
Show all 3 historical records
- India · Inactive DMF 25929 · filed Apr 2012
- Italy · Inactive DMF 25677 · filed Jan 2012
- India · Inactive DMF 24522 · filed Jan 2011
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (2 listed products contain Diclofenac Epolamine). The latest listed patent expires 20 Feb 2035. The latest listed exclusivity runs to 27 Mar 2029. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Other forms of this substance
A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:
Overview
Diclofenac Epolamine is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1201180).
Chemical identity
- IUPAC name
- 2-[2-(2,6-dichloroanilino)phenyl]acetic acid;2-pyrrolidin-1-ylethanol
- Canonical SMILES
- C1CCN(C1)CCO.C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl
- InChIKey
- DCERVXIINVUMKU-UHFFFAOYSA-N
- Synonyms
- Diclofenac epolamine, Diclofenac epolaminum, Flector, Flector patch, Licart, DHEP, Diclofenac hydroxyethylpyrrolidine, Diclofenac-epolamine, DIEP, CHEBI:48296, RefChem:57630, DHEP plaster
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Nonsteroidal Anti-inflammatory Drug
- Mechanism of action
- Cyclooxygenase Inhibitors
- Physiologic effect
- Decreased Prostaglandin Production
- Chemical structure
- Non-Steroidal
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Diclofenac Epolamine?
5 organisations hold an active US FDA Type II Drug Master File or a CEP for Diclofenac Epolamine: AMOLI ORGANICS PRIVATE LTD (India), CAMBREX CHARLES CITY INC (United States), HENAN DONGTAI PHARM CO LTD (China), SYN-TECH CHEM AND PHARM CO LTD (Taiwan) and YUNG ZIP CHEMICAL IND CO LTD. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Diclofenac Epolamine Drug Master Files are active?
AMOLI ORGANICS PRIVATE LTD (DMF 25224), CAMBREX CHARLES CITY INC (DMF 26112), HENAN DONGTAI PHARM CO LTD (DMF 44824), SYN-TECH CHEM AND PHARM CO LTD (DMF 24962) and YUNG ZIP CHEMICAL IND CO LTD (DMF 23909). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Diclofenac Epolamine records mean?
3 organisations have only inactive Type II DMFs for Diclofenac Epolamine. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does the FDA Orange Book list patents for products containing Diclofenac Epolamine?
Yes. The latest patent listed for an approved US product containing Diclofenac Epolamine expires 20 Feb 2035, across 2 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Diclofenac Epolamine supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Diclofenac Epolamine?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.